in

Biopharmaceutical company: C4 Therapeutics, Inc. (CCCC) (2015)

C4 Therapeutics, Inc. (NASDAQ:CCCC) was founded in 2015 and is headquartered in Watertown, Massachusetts, USA, with 88 full-time employees. It is a biopharmaceutical company dedicated to using the body’s natural regulation of protein levels to develop new therapeutic candidates. Targets and destroys disease-causing proteins to treat cancer, neurodegenerative diseases and other diseases.

C4 Therapeutics

C4 Therapeutics, Inc. (CCCC):

C4 Therapeutics ® is committed to changing the treatment of cancer, neurological diseases and other important diseases by eliminating new early-stage therapies that cause disease. C4 Therapeutics’ drug therapy uses the inherent mechanisms of cells to attack diseases and may bring profound and lasting responses to patients.

Therapeutics C4 ® use referred TORPEDO ( T ARGET OR iented P rot E in D egrader O ptimizer, goal-oriented optimization agent protein degradation agent) proprietary technology platform for the synthesis of a new class of small molecule protein degradation agent, the degradation agent Aims to selectively and effectively destroy disease-causing proteins, including targets previously thought to be indeterminate by drugs.

C4 Therapeutics is using the company’s TORPEDO platform to build a strong pipeline of oral protein degradation drug candidates, and the company’s main product candidates focus on tumor indications.

One of the main product candidates of C4 Therapeutics, CFT7455, is an oral bioavailable degradation agent targeting IKZF1 / 3 for multiple myeloma (MM), peripheral T cell lymphoma (PTCL) and mantle cell lymphoma (MCL) .

c4therapeutics pipeline 2020 09 08

C4 Therapeutics product line

C4 Therapeutics, Inc. (CCCC) Financing:

  • On January 7, 2016, C4 Therapeutics received a lead investment from Cobro Ventures with a round of financing on January 7, 2016. Novartis , Cormorant Asset Management, Roche and EG Capital Group followed up with a $73 million investment.
  • On June 16, 2020, with debt financing, C4 Therapeutics received an exclusive investment of US$20 million from Perceptive Advisors.
  • On June 16, 2020, Series B financing, C4 Therapeutics received Cobro Ventures and Perceptive Advisors led by Cobro Ventures and Perceptive Advisors, T. Rowe Price , RA Capital Management, HBM Healthcare Investments AG, Adage Capital Management and other 17 institutions followed up with 150 million US dollars of investment .

C4 Therapeutics, Inc. (CCCC) investment:

C4 Therapeutics, Inc. (NASDAQ:CCCC) will be listed on NASDAQ on 10/2/2020 IPO. The planned issuance price is $16.00-$18.00, the actual issuance price is US$19, 8.8 million shares are issued, and 167.2 million US dollars are raised, Jefferies/ Underwriting by Evercore ISI/ BMO Capital Markets/ UBS Investment Bank.

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all Intels

Oil and gas company: Tengasco, Inc. (TGC)

Insurance company: Maiden Holdings North America (MHNC)